Notice: Trading of Traws Pharma halted at 09:31 AM EST due to "LULD pause". Traws Pharma (TRAW) Competitors $4.48 -0.01 (-0.22%) (As of 01:02 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends TRAW vs. PMN, LTRN, ACST, CTXR, ALTS, IRD, OCUP, HOOK, BIVI, and KALAShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include ProMIS Neurosciences (PMN), Lantern Pharma (LTRN), Acasti Pharma (ACST), Citius Pharmaceuticals (CTXR), Janone (ALTS), Opus Genetics (IRD), Ocuphire Pharma (OCUP), Hookipa Pharma (HOOK), BioVie (BIVI), and KALA BIO (KALA). These companies are all part of the "pharmaceutical preparations" industry. Traws Pharma vs. ProMIS Neurosciences Lantern Pharma Acasti Pharma Citius Pharmaceuticals Janone Opus Genetics Ocuphire Pharma Hookipa Pharma BioVie KALA BIO Traws Pharma (NASDAQ:TRAW) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, community ranking, analyst recommendations, earnings and institutional ownership. Does the media refer more to TRAW or PMN? In the previous week, Traws Pharma had 4 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 6 mentions for Traws Pharma and 2 mentions for ProMIS Neurosciences. ProMIS Neurosciences' average media sentiment score of 0.25 beat Traws Pharma's score of -0.05 indicating that ProMIS Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Traws Pharma 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral ProMIS Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer TRAW or PMN? ProMIS Neurosciences received 2 more outperform votes than Traws Pharma when rated by MarketBeat users. CompanyUnderperformOutperformTraws PharmaN/AN/AProMIS NeurosciencesOutperform Votes2100.00% Underperform VotesNo Votes Which has higher valuation & earnings, TRAW or PMN? ProMIS Neurosciences has lower revenue, but higher earnings than Traws Pharma. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTraws Pharma$230K35.65-$18.95M-$141.56-0.03ProMIS Neurosciences$10K3,236.31-$13.21M-$0.10-9.90 Do institutionals & insiders believe in TRAW or PMN? 8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are owned by institutional investors. 16.1% of Traws Pharma shares are owned by company insiders. Comparatively, 4.4% of ProMIS Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, TRAW or PMN? Traws Pharma has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Is TRAW or PMN more profitable? ProMIS Neurosciences has a net margin of 0.00% compared to Traws Pharma's net margin of -62,294.25%. Traws Pharma's return on equity of -144.95% beat ProMIS Neurosciences' return on equity.Company Net Margins Return on Equity Return on Assets Traws Pharma-62,294.25% -144.95% -822.38% ProMIS Neurosciences N/A -636.20%-130.32% SummaryProMIS Neurosciences beats Traws Pharma on 8 of the 14 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.46M$6.48B$5.08B$8.80BDividend YieldN/A8.11%5.02%4.07%P/E Ratio-0.034.9791.2813.60Price / Sales36.76371.451,226.2187.40Price / CashN/A52.5939.4536.27Price / Book-4.1610.306.906.33Net Income-$18.95M$153.61M$118.83M$225.93M7 Day Performance-17.20%-1.73%-1.92%-0.96%1 Month Performance-5.71%-7.26%-3.75%1.06%1 Year PerformanceN/A31.10%31.37%26.59% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma0.8624 of 5 stars$4.48-0.2%N/AN/A$8.20M$230,000.00-0.0317Gap DownTrading HaltedPMNProMIS Neurosciences1.1238 of 5 stars$0.99-0.7%N/A-30.8%$32.36M$10,000.000.006LTRNLantern Pharma1.0942 of 5 stars$2.95+0.3%N/A-27.0%$31.80MN/A0.0020Positive NewsACSTAcasti Pharma2.366 of 5 stars$3.37-0.9%$10.00+196.7%+59.0%$31.68MN/A-2.3432CTXRCitius Pharmaceuticals3.1588 of 5 stars$0.17+1.6%$4.00+2,217.5%-77.9%$31.19MN/A-0.7120Short Interest ↓ALTSJanone1.2294 of 5 stars$2.21+0.9%N/AN/A$31.10M$39.61M0.00170IRDOpus Genetics3.0205 of 5 stars$0.97-0.9%$8.00+723.7%N/A$30.66M$19.05M0.00N/ANews CoverageOCUPOcuphire Pharma0.922 of 5 starsN/A$16.00+∞N/A$30.33M$16.45M-2.3914High Trading VolumeHOOKHookipa Pharma2.475 of 5 stars$2.47-9.2%$38.33+1,452.0%-46.4%$29.79M$20.13M-0.6856Analyst ForecastGap DownBIVIBioVie0.625 of 5 stars$3.19-5.1%$4.00+25.4%-24.0%$29.76MN/A-0.2710KALAKALA BIO4.1016 of 5 stars$6.40-0.5%$15.00+134.4%+7.8%$29.50M$3.89M0.0030Gap Down Related Companies and Tools Related Companies ProMIS Neurosciences Competitors Lantern Pharma Competitors Acasti Pharma Competitors Citius Pharmaceuticals Competitors Janone Competitors Opus Genetics Competitors Ocuphire Pharma Competitors Hookipa Pharma Competitors BioVie Competitors KALA BIO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRAW) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
